Provided by Tiger Fintech (Singapore) Pte. Ltd.

California Resources

43.78
-0.0200-0.05%
Post-market: 43.780.00000.00%16:20 EDT
Volume:807.16K
Turnover:35.32M
Market Cap:3.90B
PE:7.60
High:44.10
Open:43.44
Low:43.34
Close:43.80
Loading ...

APA (APA) Surges 19.1%: Is This an Indication of Further Gains?

Zacks
·
10 Apr

Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More

Zacks
·
10 Apr

BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo

Zacks
·
10 Apr

FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients

Benzinga
·
09 Apr

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1

Business Wire
·
09 Apr

California Resources Corporation Schedules First Quarter 2025 Earnings Conference Call

GlobeNewswire
·
07 Apr

California Resources Cut to Neutral From Buy by Citigroup

Dow Jones
·
07 Apr

Citigroup Downgrades California Resources to Neutral From Buy, Adjusts Price Target to $36 From $62

MT Newswires Live
·
07 Apr

Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum

GlobeNewswire
·
07 Apr

California Resources price target lowered to $67 from $73 at Stephens

TIPRANKS
·
03 Apr

Press Release: Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update

Dow Jones
·
01 Apr

Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening

Business Wire
·
31 Mar

Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting

GlobeNewswire
·
28 Mar

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

GlobeNewswire
·
28 Mar

Press Release: LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Dow Jones
·
28 Mar

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

GlobeNewswire
·
28 Mar

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors

Zacks
·
28 Mar

California Resources Price Target Maintained With a $68.00/Share by RBC Capital

Dow Jones
·
27 Mar

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

GlobeNewswire
·
27 Mar

California Resources Corp (CRC) Receives a Rating Update from a Top Analyst

TIPRANKS
·
27 Mar